Mason Street Advisors LLC acquired a new stake in shares of Chemed Corp. (NYSE:CHE) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 3,237 shares of the company’s stock, valued at approximately $441,000.
Other hedge funds have also made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Chemed Corp. by 147.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 947 shares of the company’s stock valued at $129,000 after buying an additional 565 shares in the last quarter. BlackRock Inc. boosted its position in Chemed Corp. by 90.4% in the first quarter. BlackRock Inc. now owns 1,152 shares of the company’s stock valued at $156,000 after buying an additional 547 shares in the last quarter. C M Bidwell & Associates Ltd. purchased a new position in Chemed Corp. during the first quarter valued at about $163,000. Public Employees Retirement System of Ohio boosted its position in Chemed Corp. by 3.5% in the second quarter. Public Employees Retirement System of Ohio now owns 1,319 shares of the company’s stock valued at $180,000 after buying an additional 45 shares in the last quarter. Finally, Fifth Third Bancorp boosted its position in Chemed Corp. by 6.8% in the second quarter. Fifth Third Bancorp now owns 1,374 shares of the company’s stock valued at $187,000 after buying an additional 88 shares in the last quarter. Institutional investors and hedge funds own 98.62% of the company’s stock.
Shares of Chemed Corp. (NYSE:CHE) opened at 140.94 on Wednesday. Chemed Corp. has a 12-month low of $124.77 and a 12-month high of $160.12. The stock’s 50 day moving average is $137.00 and its 200-day moving average is $135.90. The stock has a market cap of $2.28 billion, a price-to-earnings ratio of 22.35 and a beta of 1.17.
Chemed Corp. (NYSE:CHE) last announced its earnings results on Monday, July 25th. The company reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.08. The business had revenue of $290 million for the quarter, compared to analyst estimates of $393.50 million. Chemed Corp. had a net margin of 6.93% and a return on equity of 24.12%. The company’s revenue for the quarter was up 2.2% compared to the same quarter last year. During the same period last year, the firm posted $1.71 earnings per share. Equities analysts anticipate that Chemed Corp. will post $7.25 EPS for the current fiscal year.
Several equities analysts recently issued reports on the stock. RBC Capital Markets reiterated a “sector perform” rating and issued a $162.00 target price (up from $136.00) on shares of Chemed Corp. in a research note on Wednesday, July 27th. Royal Bank Of Canada upped their price objective on shares of Chemed Corp. from $136.00 to $162.00 and gave the stock a “sector perform” rating in a research report on Wednesday, July 27th. Zacks Investment Research upgraded shares of Chemed Corp. from a “hold” rating to a “buy” rating and set a $167.00 price objective for the company in a research report on Thursday, July 28th. Oppenheimer Holdings Inc. restated an “outperform” rating and set a $155.00 price objective on shares of Chemed Corp. in a research report on Tuesday, September 27th. Finally, JMP Securities restated a “hold” rating on shares of Chemed Corp. in a research report on Sunday, September 4th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $161.50.
In other news, insider Spencer S. Lee sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 22nd. The shares were sold at an average price of $141.67, for a total transaction of $283,340.00. Following the transaction, the insider now directly owns 39,867 shares in the company, valued at $5,647,957.89. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Kevin J. Mcnamara sold 18,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 3rd. The stock was sold at an average price of $144.87, for a total transaction of $2,607,660.00. Following the transaction, the insider now owns 163,266 shares in the company, valued at $23,652,345.42. The disclosure for this sale can be found here. Insiders own 5.32% of the company’s stock.
About Chemed Corp.
Chemed Corporation operates and divests subsidiaries engaged in diverse business activities. The Company operates its business in two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS segment provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corp. (NYSE:CHE).
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.